Q-omics provides the consensus-scored MARCHF3 profile across patient tissues and cancer cell-line models. MARCHF3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MARCHF3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MARCHF3 RNA expression shows 19,346 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where MARCHF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF3 survival associations across molecular data types. MARCHF3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF3 RNA expression–survival associations across cancer types. High MARCHF3 expression shows unfavorable associations in KIRP, KICH, LIHC and UVM, but favorable associations in HNSC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MARCHF3 RNA expression.
This table summarizes MARCHF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MARCHF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF3 shows lower tumor expression in READ, LUSC and HNSC and higher tumor expression in KIRC, STAD and LIHC. The KIRC box plot shows higher MARCHF3 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with MARCHF3 in patient tissues and cancer cell lines. In patient samples, MARCHF3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
